Ki-67指数分层提高p16INK4a作为脑膜瘤CDKN2A失活替代标志物的特异性
研究探讨Ki-67标记指数分层能否提高p16INK4a免疫组化预测脑膜瘤CDKN2A失活的特异性。以Ki-67作为肿瘤侵袭性替代标志物,在p16低表达的肿瘤中识别出5%的阈值作为预测CDKN2A失活的敏感性截断值,提示高标记指数亚组可从进一步分子验证中获益,而p16高表达亚组进行CDKN2A检测产出低。
要点
- Ki-67指数5%可作为p16低表达脑膜瘤预测CDKN2A失活的敏感性截断值。
- p16高表达亚组进行CDKN2A分子检测产出低,可优先筛查p16低表达者。
- Ki-67与p16联合可作为经济有效的筛查工具,适用于资源受限环境。
核心结论
- 以Ki-67指数5%分层可提高p16INK4a预测脑膜瘤CDKN2A失活的实用性,高标记指数亚组适合进一步分子验证。
研究设计与样本
- 本研究为病理标志物相关性研究,评估Ki-67标记指数分层下p16INK4a表达预测脑膜瘤CDKN2A失活的价值。
主要发现
- 在p16低表达的肿瘤中,Ki-67指数5%被识别为预测CDKN2A失活的敏感性截断值。
- p16高表达亚组进行CDKN2A状态检测产出低。
- Ki-67与p16表达联合可作为经济有效的筛查工具标记潜在侵袭性脑膜瘤。
关键数值与推荐
- p16低表达脑膜瘤中,Ki-67指数5%作为预测CDKN2A失活的敏感性截断值。
- p16高表达亚组进行CDKN2A分子检测产出低,不建议优先检测。
临床怎么用
- 对脑膜瘤联合评估Ki-67指数与p16表达,p16低表达且Ki-67≥5%者建议进一步分子验证CDKN2A状态。
- 资源受限环境下可用Ki-67与p16免疫组化作为筛查工具,减少不必要的分子检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meningiomas are the most common primary central nervous system tumors, with histologic grading predicting prognosis and guiding treatment decisions. Recent updates to the WHO Classification of Tumors of the Central Nervous System have incorporated molecular criteria, including homozygous deletion of CDKN2A in grade 3 meningiomas. CDKN2A encodes the tumor suppressor protein p16INK4a, a key regulator of cell cycle progression, and loss is associated with increased proliferation, recurrence, and poor clinical outcomes. Previous studies have shown that p16INK4a protein levels can serve as a surrogate immunohistochemical marker that correlates with CDKN2A status in higher-grade meningiomas. However, p16 utility in segregating cases for further testing remains unclear. In this study, we aimed to stratify meningiomas to identify cases that may benefit from molecular testing. We investigated whether Ki-67 labeling could serve as a stratification tool to identify meningiomas for which minimal expression of p16 is indicative of underlying CDKN2A inactivation. Using Ki-67 as a surrogate marker for tumor aggressiveness, we identified a threshold of 5% in tumors with low p16 expression as a sensitivity cutoff for predicting CDKN2A inactivation, suggesting that the subset of meningiomas with a higher labeling index could benefit from further molecular validation, whereas the subset with p16hi expression is low yield to profile for CDKN2A status. Our findings support the clinical utility of Ki-67 and p16 expression as cost-effective screening tools to flag potentially aggressive meningiomas, particularly in resource-constrained settings.
引用
- Zhang KY, Mirchia K, Perry A, et al. Stratification by Ki-67 Labeling Index Increases Specificity of p16INK4a Expression as a Surrogate Marker for CDKN2A Inactivation in Meningioma. Mod Pathol. 2026. PMID: 42297142. doi:10.1016/j.modpat.2026.101024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。